Latest News

Category: News

See all

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Spain

News,

Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Spain by AEMPS for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. Illuccix® is now approved in all 19 countries included in Telix’s decentralized procedure...

Read more

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

ASX, News,

Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August...

Read more

Telix H1 2025 Results: Investor Webcast Notification

ASX, News,

Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August...

Read more

Telix Reports $204M Revenue, Up 63% YOY

ASX, News,

Telix today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated...

Read more

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Austria

News,

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by BASG for the detection and...

Read more

Gozellix Receives Permanent HCPCS Code

ASX, News,

Telix today announces that its next-generation PSMA PET imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System...

Read more

Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses

News,

Telix today announces that its Telix Manufacturing Solutions (TMS) facility in Brussels South (Seneffe), Belgium, has produced its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical doses and delivered them to...

Read more

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Italy

News,

Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Italy by the AIFA for...

Read more

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Belgium

News,

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by AFMPS for the detection and...

Read more

Telix Precision Medicine Announces AlFluor™ Radiochemistry Platform

News,

Telix today announces it has launched a novel PET radiochemistry solution based on 18F-aluminium fluoride (AlF), named...

Read more